Exenatide GLP-RA , 1995 2005 .60 Liraglutide 2010 2 ,62 lixisenatide 2013 2 , 2 016 7 .63 (Albiglutide) 2014 3 , 2014 4 .64 (Dulaglutide) 2014 9 T2DM ,65 (Semaglutide) 2017 9 .66 (Beinaglutide) GLP-RA , 2016 9 T2DM .67 PEG-(PEG-loxenatide) GLP-RA , 2019 5 .66 ( 1 2) Table 1 Comparison of GLP-1RAs used in type 2 diabetes mellitus DateBrand nameGLP-1RAHalf-lifeDose (SC)Molecular formulaClinial trial focus Table 2 Comparative overview of efficacy and adverse effects of mainstream GLP-1RA medications Current GLP-1RAs GLP-1RAs are synthetic protein preparations that have partial or complete amino acid sequence homology with GLP-1 found in the body, are not easily degraded, have longer half-lives and have stronger biological activity
Kathleen Pellechia, MS, RDN GLP-1 Therapy for Patients with Obesity: Identifying Solutions to Optimize Nutrition Purchase this Product Learn to address challenges associated with the use of GLP-1 medications in the treatment of obesity
Phase 2 trial data showed an average of 24.2% body weight loss at 48 weeks on the 12mg dose, roughly 58 lbs for someone starting at 240 lbs
Die Kapseln bieten eine einfache Mglichkeit, Alpha-Liponsure zu dosieren und in den Alltag zu integrieren
Mirabelli M, Chiefari E, Caroleo P, et al